EUROPE CELL AND GENE THERAPY MARKET SIZE TO CROSS USD 2.9 BILLION IN 2026, GROWING AT A CAGR OF 23% DURING THE PERIOD 2021–2026

Europe Cell and Gene Therapy Market Size, Share, Trends Analysis Report by Product (Cell Therapies and Gene Therapies); End-user (Hospitals, Cancer Care Centers, Wound Care Centers, and Others); Applications (Oncology, Dermatology, Musculoskeletal, and Others); and Geography (Europe); Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2021–2026

GET ACTIONABLE INSIGHTS ON HOW COVID-19 IS IMPACTING YOUR BUSINESS
Enquire Now Download Free Sample

Most Exhaustive Report

187 Pages

47 Tables

84 Charts

1 Regions

7 Countries

36 Companies

4 Market Segment

EUROPE CELL AND GENE THERAPY MARKET REPORT SCOPE

Report Attribute Details
MARKET SIZE (REVENUE) 2.9 BILLION (2026)
CAGR 23% (2021–2026)
Base Year 2020
Forecast Year 2021–2026
Market Segments Product (Cell Therapies and Gene Therapies); End-user (Hospitals, Cancer Care Centers, Wound Care Centers, and Others); Applications (Oncology, Dermatology, Musculoskeletal, and Others)
Geographic Analysis Europe
Countries Covered UK, Germany, France, Italy, Spain, Switzerland, and Netherlands

INDUSTRY INSIGHTS

The Europe cell and gene therapy market size to cross USD 2.9 billion in 2026, growing at a CAGR of 23% during 2021-2026. The global cell and gene therapy market observes significant mergers and acquisition activities, product sales, and new market authorizations. In 2026, the market is expected to grow almost four times more than the current value, with new product approvals expected annually. Although initial product approvals have been for relatively small patient groups, the significant pipeline of cell & gene therapy studies for diseases such as hemophilia and various forms of blindness will significantly expand. Besides, the European market is witnessing steady growth due to increased funds from several public and private institutes. There is increased support from regulatory bodies for product approvals and fast-track product designations, which encourage vendors to manufacture products faster. Moreover, with over 237 regenerative medicines companies headquartered in Europe, the region is seen as the favorite destination for cell and gene therapy manufacturing.

SNIPPETS

  • Gene therapies are likely to grow at the highest CAGR during the forecast period due to the high potential of these therapies to treat several diseases and ailments effectively.
  • The revenue share of oncology therapies is expected to touch approx. $13 billion by 2026 on account of rapid development in CAR-T cell therapies has high commercial potential for treating cancer.
  • While hospitals are expected to dominate the Europe cell and gene therapy market during the forecast period, cancer care centers are projected to grow at the highest rate.
  • Western Europe is likely to account for revenue of over $2.7 billion by 2026 because of the crucial role played by Germany, France, the UK, Italy, and Spain in the development of cell and gene therapies.

EUROPE CELL AND GENE THERAPY MARKET SEGMENTATION

This research report includes a detailed segmentation by

  • Product
  • End-user
  • Application
  • Geography

INSIGHTS BY PRODUCTS

A high potential to treat several chronic diseases, which cannot be effectively treated/cured through conventional methods otherwise, is propelling gene therapies' growth.  Gene therapies are regarded as a potential revolution in the health sciences and pharmaceutical fields. The number of clinical trials investigating gene therapies is increasing in Europe, despite the limited number of products that have successfully reached the market. However, gene therapies show slow progress and promising prospect in terms of treatments. High support from regulatory bodies to commercialize these products and make them affordable to patients is another important factor contributing the market growth.

A surge in cell therapy transplantation procedures, growing research and development activities, and rising investments in building production facilities for cell therapy products drive the European cell therapy market growth. However, a low success rate of cell therapies and the high cost of cell-based research are expected to restrain the market growth during the forecast period.

INSIGHTS BY END-USER

Delivering cell and gene therapies requires specialized facilities, capabilities, and clinician skills. Therefore, manufacturers are working in tandem with chosen treatment centers (hospitals) to establish the protocols and procedures necessary to receive the product and therapies. While cell therapies represent a paradigm shift in treating several incurable, chronic diseases, with durable responses and long-term disease control measures, hospitals appear an ideal location to carry out these procedures. Hospitals are growing at a significant rate due to the increasing target population in Europe. Tier-I hospitals are proving to be sought-after network partners for cell and gene therapy developers. They tend to be in major population centers, have adequate financial and personnel resources, and value the prestige that comes with being the first movers in an innovative treatment area.

Cancer care centers accounted for over 20% of the Europe cell and gene therapy market share in 2020. These centers provide life-extending immunotherapy treatments to patients, enabling them to access the latest therapies instantly. The healthcare expenditure for cancer treatments has increased in Europe. There has been a new trend in cancer treatment. The introduction of CAR-T cell therapies and the increased usage of combination treatments and multi-indication treatments are the two recent and major cancer oncology treatments in Europe.

INSIGHTS BY APPLICATION

Oncology accounted for a share of over 30% in 2020. While cancer treatments have evolved and undergone massive developments in recent years, it continues to be one of the deadliest diseases confronted by humans. Traditional cancer therapies have a curative effect in the short term; however, they have side effects, thereby decreasing patients' quality of life. Cell and gene therapies for certain types of cancers have been promising results. The chimeric antigen receptor- (CAR-) T cell therapy is one of the most recent innovative immunotherapies and is rapidly evolving. CAR-T cell therapies are developing rapidly, and many clinical trials have been established on a global scale, which has high commercial potential for the treatment of cancer. Immunotherapies based on CAR-T cells go one step further, engineering the T cells themselves to enhance the natural immune response against a specific tumor antigen. CAR-T clinical trials have shown high remission rates, up to 94%, in severe forms of blood cancer, thereby increasing the market growth.

Wound care management constitutes a growing burden on public health expenditure and is incurring a high cost to the health care system. Acute wounds can be traumatic such as abrasions, lacerations, penetrating injuries and burns, or surgical wounds from surgical incisions. Burns remains one of the common injuries in Europe. Gene therapies are in the early stages; however, they display promising results for some rare genetic dermatology diseases and common skin conditions. Hence, positive clinical dividends and high potential to treat some acute wounds are expected to influence the cell and gene therapy market growth during the forecast period.

INSIGHTS BY GEOGRAPHY

Germany, France, the UK, Italy, and Spain play a significant role in the European cell and gene therapy market. Clinical trials and the number of manufacturing facilities are increasing slowly in the European region. The region has become a major R&D destination for several vendors as the funding for cell & gene therapies is increasing. Europe has supported collaborative efforts in gene transfer and gene therapy research. Besides, the target patient population is increasing across Europe; there were an estimated 3.9 million new cancer cases and 1.9 million cancer deaths in Europe in 2018. Besides, the prevalence surveys in the UK and Denmark indicate that there are 3–4 people with one or more wounds per 1,000 people. Favorable government support in terms of product approvals, reimbursement and coverage, and high R&D funding to academic institutes involved in the development of cell and gene therapies are expected to boost the market in Europe.

INSIGHTS BY VENDORS

Novartis, Spark Therapeutics, Amgen, Gilead Sciences, and Organogenesis are the leading players in the Europe cell and gene therapy market. The market offers tremendous growth opportunities for existing and future/emerging players because of the presence of a large pool of target patient populations with chronic diseases such as cancer, wound disorders, diabetic foot ulcers, CVDs, and other genetic disorders. Recent approvals have prompted an unprecedented expansion among vendors.  While a few vendors are opting for in-house production of cell and gene therapies, a substantial number of vendors prefer third-party service providers, including CMOs.

The Europe cell and gene therapy market research report includes in-depth coverage of the industry analysis with revenue and forecast insights for the following segments:

Product

  • Cell Therapies
  • Gene Therapies

End-user

  • Hospitals
  • Cancer Care Centers
  • Wound Care Centers
  • Others

Application

  • Oncology
  • Dermatology
  • Musculoskeletal
  • Others

Geography

  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Switzerland
    • Netherlands

Frequently Asked Questions

The Europe cell and gene therapy market is growing at a CAGR of over 23%, reaching to market revenue of USD 2.9 billion by 2026.
Increase in demand for CAR-T Therapies in Europe and rise in new product launches and approvals are the major factors driving the market growth.
Vendors are strategically focusing on the launch of single-use bioprocessing products to remain competitive and gain traction in the market.
In terms of application, oncology is likely to account for the highest revenue contribution to the market.
Novartis, Spark Therapeutics, Amgen, Gilead Sciences, and Organogenesis are the leading vendors in the market.
Download Free Sample
Read More

Select a license type that suits your business needs

Single User Licence
$3500.00
  • Report accessible by one user only
  • Free 10% or 3 days of customization
  • Free post-sale service assistance
  • Continuous support through email
Best Value Tag
5 User Licence
$4000.00
  • Report accessible by 5 users within the organization
  • Free 15% or 4.5 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Corporate Licence
$5000.00
  • Free Datasheet worth $1500
  • Report accessible by the entire organization
  • Free 20% or 6 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Direct access to lead analysts
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Datasheet Licence
$1500.00
  • Report accessible by 1 user only
  • Free 15% or 32 hours of customization
  • Free post-sale service assistance
  • Direct access to lead analysts

Select a license type that suits your business needs

Best Value Tag
Coming Soon
  • Stay tuned with us.

YOU CAN GET A FREE SAMPLE OF THIS REPORT!

Fill out your details & get your free sample

Our Clients

Licence Types What are these?

Our Clients Speak

"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."

Erik Young
CEO, Co-founder
Audink Inc., DBA Audios
SPEAK WITH OUR ANALYST

Want to know more about the report or any specific requirement?

Click to Email +1-312-235-2040

Why Arizton?

  • 100% Customer Satisfaction
  • 24x7 availability – we are always there when you need us
  • 200+ Fortune 500 Companies trust Arizton's report
  • 80% of our reports are exclusive and first in the industry
  • 100% more data and analysis
  • 1000+ reports published till date